Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant
British Journal of Biomedical Science · 22.04.2026 · 83
DOI: 10.3389/bjbs.2026.16255 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Biomedical Science, online erschienen am 22.04.2026. Verfasst von Marina Kawaguchi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, SARS-CoV-2. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long COVID (LC) presents persistent symptoms that pose a major clinical challenge. Identification of reliable biomarkers to evaluate LC pathophysiology is needed.
Objectives
To investigate whether serum S- and N-antibody titers against SARS-CoV-2 spike and nucleocapsid proteins reflect the clinical features of LC.
Methods
This retrospective observational study included patients diagnosed with Omicron variant-related LC who attended a post-COVID-19 outpatient clinic between July 2023 and November 2024 and provided informed consent for antibody testing.
Results
Among 275 patients (129 men and 146 women), 57 (21%) were unvaccinated. Median S- and N-antibody titers in vaccinated versus unvaccinated patients were 20,963 U/mL and 24.8 cut-off index (COI) versus 24 U/mL and 44.5 COI, respectively. S-antibody titers were associated with the number of vaccine doses received, whereas N-antibody titers correlated with disease severity during the acute phase of COVID-19 infection, with females having higher titers by multivariable analysis. N-antibody titers in unvaccinated patients with LC were negatively correlated with time interval from infection to clinic visit, with an estimated daily decline of 0.34% in measured N-antibody levels. Patients with LC having memory impairment had low S-antibody titers by multivariable logistic regression analysis, and low S-antibody levels were associated with reduced quality of life (QOL). Additionally, N-antibody titers positively correlated with lymphocyte counts and immunoglobulin levels.
Conclusion
Serum N-antibody titers reflect immune responses to COVID-19, although they are affected by gender differences and interval between infection and evaluation. Lower S-antibody titers were associated with brain fog symptoms and reduced QOL in patients with LC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
- Department of Laboratory Medicine, Okayama University Hospital, Okayama, Japan.
Zitieren
APA
Kawaguchi, M., Sakurada, Y., Tokumasu, K., Otsuka, Y., Nakano, Y., Matsuda, Y., Honda, H., Omura, D., Matsuki, N., Furukawa, M., Higashikage, A., & Otsuka, F. (2026). Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant. British Journal of Biomedical Science, 83. https://doi.org/10.3389/bjbs.2026.16255
Vancouver
Kawaguchi M, Sakurada Y, Tokumasu K, Otsuka Y, Nakano Y, Matsuda Y, et al. Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant. British Journal of Biomedical Science. 2026;83. doi:10.3389/bjbs.2026.16255
BibTeX
@article{Kawaguchi2026,
author = {Kawaguchi, Marina and Sakurada, Yasue and Tokumasu, Kazuki and Otsuka, Yuki and Nakano, Yasuhiro and Matsuda, Yui and Honda, Hiroyuki and Omura, Daisuke and Matsuki, Nobuyoshi and Furukawa, Masanori and Higashikage, Akihito and Otsuka, Fumio},
title = {Clinical Utility of SARS-CoV-2 Antibody Titers in the Management of Patients With Long COVID Infected With the Omicron Variant},
journal = {British Journal of Biomedical Science},
year = {2026},
volume = {83},
doi = {10.3389/bjbs.2026.16255}
}
EUVIMED